{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-25-000146","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.107816+00:00","generated_at":"2026-05-16T13:11:01.436876+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ImmunityBio appoints Bruce Wendel to board of directors effective Dec. 12.","bullets":["Bruce Wendel appointed independent director effective Dec. 12, 2025; term expires at 2026 annual meeting.","Background includes Abraxis BioScience (commercialized Abraxane, led Celgene acquisition), Bristol-Myers Squibb.","Receives $50k annual cash retainer plus initial stock option with $300k Black-Scholes value, vesting 1/3 annually over 3 years.","Previously served on boards of GT BioPharma and Verastem."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-25-000146","json":"https://secwatch.observer/filing/0001326110-25-000146.json","markdown":"https://secwatch.observer/filing/0001326110-25-000146.md","text":"https://secwatch.observer/filing/0001326110-25-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/0001326110-25-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/ibrx-20251210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:11:01.436876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}